2026-01-27 - Analysis Report
**AbbVie (ABBV) Comprehensive Analysis**

### Company Overview
AbbVie is a global biopharmaceutical company.

### Cumulative Return Comparison

* Ticker to review: ABBV
* Cumulative return of review stock: **182.18%**
* Cumulative return of comparison stock (S&P 500, VOO): **127.58%**
* Divergence (max: 90.90, min: -28.60, current: 53.90, relative divergence: 69.00%): The stock has a relatively high divergence from the S&P 500, indicating significant outperformance.

### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 35.0% | 23.1% | 26.0% | 1.0 | 162.9B |
| 2017-2019  | 27.0% | 23.1% | 2.0% | 1.1 | 156.5B |
| 2018-2020  | -19.0% | 32.9% | -43.0% | 0.8 | 189.4B |
| 2019-2021  | 77.0% | 32.9% | 13.0% | 0.7 | 239.3B |
| 2020-2022  | 100.0% | 32.9% | 96.0% | 0.6 | 285.6B |
| 2021-2023  | 54.0% | 19.5% | 36.0% | 0.4 | 273.9B |
| 2022-2024  | 33.0% | 19.5% | 4.0% | 0.3 | 314.1B |
| 2023-2025  | 84.0% | 20.4% | 9.0% | 0.3 | 403.8B |

### Recent Stock Price Fluctuations

* Close: **$220.77**
* Last-market price: $220.77 ($0.69 increase)
* 5-day SMA: **$217.67**
* 20-day SMA: **$222.61**
* 60-day SMA: **$224.94**

### RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence

* Market Risk Indicator (MRI): **0.70** (Medium Investment Recommended)
* RSI: **50.69**
* PPO: **-0.09**
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium
* Recent (20 days) relative divergence change: 5.30 (+): improving
* 7-day Rank change: -12 (-): rank down
* 7-day Dynamic Expected Return change: -15.80 (-): worsening
* Expected Return (%): **24.40%**, expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

### Recent News & Significant Events

* AbbVie Rose 2% Last Week. Hereâ€™s Why Investors Looked Past Trial Risk - TIKR.com
* How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV) - Yahoo Finance UK
* AbbVie Inc. $ABBV Stake Cut by Lbp Am Sa - MarketBeat
* 3 No-Brainer Dividend Stocks to Buy Right Now - The Motley Fool
* AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com
* March 6th Options Now Available For AbbVie (ABBV) - Nasdaq

### Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): **1.93** (~Buy)
- Opinions: **27**
- Target Price (avg/high/low): **245.22 / 289.00 / 184.00**

### Comprehensive Analysis

AbbVie (ABBV) shows a strong cumulative return of **182.18%**, indicating significant outperformance compared to the S&P 500. The alpha, beta analysis also indicates consistent returns across different time periods. The recent stock price fluctuations show a slight increase, with the 20-day and 60-day SMA suggesting a short-term upward trend. The RSI and PPO indicators are neutral, while the hybrid signal is buy. The market risk indicator is medium, indicating a moderate investment recommendation. The expected return is **24.40%**, suggesting expected excess return compared to S&P 500 if invested long-term. Recent news and significant events indicate a strong dividend yield and consistent earnings growth. Overall, AbbVie appears to be a attractive investment opportunity with a buy recommendation from analysts.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.